Boots to start prescribing medical cannabis in first for UK high street pharmacy
Boots is set to become the first high street pharmacy in Britain to offer private medicinal cannabis prescriptions, the company has confirmed.
The most affordable dosage option made available via Boots' online doctor platform will cost just under £40.
Branded SureLeaf, the service will cater to adults aged 25 and over who live with chronic pain, insomnia or generalised anxiety disorder.
Recreational cannabis remains illegal in the UK, classified as a Class B controlled drug, and it is prohibited to possess, grow, sell or supply without the appropriate licence.
However, the Boots scheme could see medical cannabis becoming available to the 26 per cent of adults in Britain who report experiencing chronic pain and the five million people who have chronic insomnia.
Medical cannabis has been legal since 2018 but has remained largely confined to specialist private clinics.
To qualify for SureLeaf, patients must first have exhausted conventional treatment options without adequate relief.
Those seeking treatment will begin with an online assessment, after which a clinical team evaluates their suitability before arranging a video consultation with a specialist consultant.

A multidisciplinary panel, including a second consultant, then independently reviews any resulting prescription before treatment begins.
Patients are screened for histories of psychosis and other conditions that might rule out cannabis-based therapy.
Approved individuals may be prescribed cannabis in flower or oil form for an initial period of 28 days, with regular reviews built into the process.
Boots has stressed that ongoing monitoring is a core part of the service, with clinicians tracking patient progress throughout treatment.
LATEST DEVELOPMENTS
- Muslims stage huge protest outside Indian restaurant refusing to serve customers halal food
- Migrant knifeman who sparked Dublin riots jailed for life over attempted murder of children
- Britain could be punished for committing 'genocide' in Ireland over role in potato famine

Currently, NHS cannabis prescriptions remain restricted to patients with rare forms of epilepsy, specific side effects of chemotherapy, and certain symptoms of multiple sclerosis.
Beyond these narrow categories, private clinics have for years been treating patients for conditions including psychiatric and neurological disorders.
Jamie Kerruish, the pharmacy’s chief healthcare officer, told LBC: “At Boots, we're committed to making healthcare more accessible and helping people find the right support for their individual needs.”
“Medical cannabis is a specialist area of healthcare and, through SureLeaf, we're giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care,” he told LBC.
Dr David Gwynne, the medical director of Boots' online doctor service, emphasised that the drug would not suit every patient and that prescribing choices required careful, case-by-case judgement.
“SureLeaf has, therefore, been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate,” he said.
The pharmacy’s medical director insisted that responsible, clinician-led care would extend from initial assessment through to continued monitoring.
Today’s announcement comes after Whittington Investments, the Canadian holding company of the Weston family, took over Boots.
Canada has permitted medicinal cannabis since 2001 and established a legal recreational market in 2018.
Our Standards: The GB News Editorial Charter
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0